CO-IMPACT Expert Network

International Group of Investigators

CO-IMPACT 1

Impact of PSMA PET CT/MRI at first diagnosis on outcomes in unfavourable intermediate- and high-risk prostate cancer.

Principal Investigators (PIs):

Dr. Simon K.B. Spohn

Department of Radiation Oncology, Medical Center – University of Freiburg, Freiburg, Germany

simon.spohn@uniklinik-freiburg.de

Dr. Marco Vogel

Department of Radiation Oncology, Technical University Munich, Munich, Germany

marco.vogel@tum.de

Dr. Stephanie G.C. Kroeze

Radiation Oncology Center Mittelland, Canton Hospital Aarau, Aarau, Switzerland

stephanie.thoma@ksa.ch

Dr. Giulia Marvaso

Dipartimeno di Oncologia ed Onco-ematologia presso Università degli Studi di Milano, Milano, Italy

Giulia.Marvaso@ieo.it

CO-IMPACT 2

Impact of PSMA PET CT/MR imaging for salvage radiotherapy guidance in prostate cancer patients with recurrent or persistent PSA after primary prostatectomy.

Principal Investigators (PIs):

Dr. Constantinos Zamboglou

German Oncology Center, Limassol, Cyprus

Constantinos.Zamboglou@goc.com.cy

Dr. Nina-Sophie Schmidt-Hegemann

Department of Radiation Oncology, University Munich (LMU), Munich, Germany

Nina-Sophie.Hegemann@med.uni-muenchen.de

Dr. Shankar Siva

Department of Radiation Oncology, Peter MacCallum Cancer Center, Melbourne, Australia

Shankar.Siva@petermac.org

Dr. Mohamed Shelan

Department of Radiation Oncology, University of Bern, Bern, Switzerland

Mohamed.Shelan@insel.ch

CO-IMPACT 3

Impact of PSMA PET CT/MR imaging in prostate cancer patients with recurrent PSA after primary radiotherapy.

Principal Investigators (PIs):

Dr. Vedang Murthy

Department of Radiation Oncology, Tata Memorial Centre, India

vmurthy@actrec.gov.in

Dr. Amar U. Kishan

Department of Radiation Oncology, UCLA, Los Angeles, USA

AUKishan@mednet.ucla.edu

Dr. Tobias Hoelscher

Department of Radiation Oncology, University of Dresden, Dresden, Germany

Tobias.Hoelscher@uniklinikum-dresden.de

Dr. Jan Peeken

Department of Radiation Oncology, Technical University Munich, Munich, Germany

jan.peeken@tum.de

CO-IMPACT 4

Impact of PSMA PET CT/MR imaging in castration-resistant prostate cancer patients with radiotherapy due to oligoprogressive disease.

Principal Investigators (PIs):

Dr. Matthias Guckenberger

Department of Radiation Oncology, University of Zürich, Switzerland

Matthias.Guckenberger@usz.ch

Dr. Thomas Zilli

IOSI - Oncology Institute of Southern Switzerland, EOC, Switzerland

Thomas.Zilli@eoc.ch

Dr. Ken Herrmann

Essen University Hospital, Germany

ken.herrmann@uk-essen.de

Dr. S. Gillessen

IOSI - Oncology Institute of Southern Switzerland, EOC, Switzerland

silke.gillessen.sommer@usi.ch